Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI
Myocardial Tissue Characterization and Deformation Kinetics Following the Ross Procedure: A Prospective Multiparametric CMR Study
The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.
Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.
This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.
Descrizione
Inclusion Criteria:
- Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
- Informed written consent to participate in serial prospective imaging.
Exclusion Criteria:
- Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
- Prior myocardial infarction or primary non-ischemic cardiomyopathy.
- Severe renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m²).
- Associated congenital heart disease causing volume overload ex: VSD and PDA.
- Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
- Standard contraindications to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diffuse myocardial fibrosis
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Diffuse myocardial fibrosis
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Subclinical myocardial mechanical recovery
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by global radial strain [GRS]. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Lasso di tempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CMR-ROSS
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .